Clinical effect of liraglutide on type 2 diabetes mellitus complicated with polycystic ovary syndrome
Li Qiuyun
Liu Xing
Li Haoxuan
Yang Chunwei
Zhang Weihuan
Wang Tingting
Guo Zhihui
Zhou Yanru
Abstract：Objective To explore the clinical effect of liraglutide on type 2 diabetes mellitus complicated with polycystic ovary syndrome.Methods Sixty type 2 diabetic patients with polycystic ovary syndrome who visited Kailuan General Hospital from January 2015 to December 2016 were randomly divided into control group and observation group,with 30 cases in each group.The control group had diet and exercise intervention;the observation group was treated by liraglutide for 24 weeks.Waist circumference,body mass index,fasting blood glucose,glycosylated hemoglobin and blood lipid were analyzed before and after treatment.Diameter of mature follicle was measured by color Doppler ultrasound.Results There were no significant differences of age,waist circumference,body mass index,fasting blood glucose,glycosylated hemoglobin,blood lipid and mature follicle diameter between groups before treatment (P ＞ 0.05).After treatment,fasting blood glucose,glycosylated hemoglobin,body mass index,waist circumference in control group were significantly lower and mature follicle diameter was significantly higher than those before treatment (P ＜ 0.05);low-density lipoprotein cholesterol,triacylglycerol,total cholesterol,fasting blood glucose,glycosylated hemoglobin,body mass index,waist circumference in observation group were significantly lower and high-density lipoprotein cholesterol,mature follicle diameter were significantly higher than those before treatment(P ＜ 0.05).Total cholesterol,fasting blood glucose and glycosylated hemoglobin after treatment in observation group were significantly lower than those in control group [(5.4 ±0.8) mmol/L vs (5.8 ±0.8)mmoL/L,(6.6 ±0.5) mmol/L vs (7.7 ±0.8) mmol/L,(5.2 ±0.4)％ vs (5.8 ± 1.0) ％];high-density lipoprotein cholesterol and mature follicle diameter after treatment in observation group were significantly higher than those in control group [(1.43 ± 0.22) mmol/L vs (1.25 ± 0.27) mmol/L,(1.10 ± 0.10) cm vs (0.83 ± 0.11) cm] (P ＜ O.05).Conclusion Lirolipotine treating type 2 diabetes complicated with polycystic ovary syndrome can effectively reduce blood glucose,glycosylated hemoglobin,total cholesterol and promote follicular development.
Keywords：Diabetestype 2LiraglutidePolycystic ovary syndrome
Publication Date：2018-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 549-552 )